Entellus Medical Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 23rd. The shares were sold at an average price of $19.00, for a total value of $95,000.00. Following the completion of the transaction, the director now owns 494,581 shares in the company, valued at $9,397,039. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Entellus Medical Inc. (NASDAQ:ENTL) opened at 18.99 on Tuesday. The stock has a 50 day moving average price of $19.06 and a 200 day moving average price of $18.71. Entellus Medical Inc. has a 52 week low of $13.72 and a 52 week high of $22.63. The firm’s market capitalization is $358.23 million.

Entellus Medical (NASDAQ:ENTL) last issued its quarterly earnings data on Thursday, November 3rd. The medical technology company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.13. Entellus Medical had a negative return on equity of 53.20% and a negative net margin of 36.91%. The business had revenue of $17.90 million for the quarter, compared to analysts’ expectations of $17.93 million. During the same period last year, the business earned ($0.32) earnings per share. The company’s revenue for the quarter was up 20.9% on a year-over-year basis. Equities analysts forecast that Entellus Medical Inc. will post ($1.42) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

WARNING: “Entellus Medical Inc. (ENTL) Director Brian E. Farley Sells 5,000 Shares of Stock” was first reported by Financial Market News and is the propert of of Financial Market News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece of content can be viewed at http://www.financial-market-news.com/entellus-medical-inc-entl-director-brian-e-farley-sells-5000-shares-of-stock/1208108/.

ENTL has been the topic of a number of research reports. Zacks Investment Research cut Entellus Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, October 5th. Deutsche Bank AG restated a “buy” rating and set a $26.00 price target (up from $25.00) on shares of Entellus Medical in a research note on Friday, November 4th. BTIG Research restated a “buy” rating and set a $22.00 price target on shares of Entellus Medical in a research note on Friday, August 5th. Finally, Canaccord Genuity restated a “buy” rating and set a $23.00 price target on shares of Entellus Medical in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Entellus Medical presently has an average rating of “Buy” and an average price target of $22.75.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Murphy Michael R boosted its position in shares of Entellus Medical by 30.1% in the second quarter. Murphy Michael R now owns 627,441 shares of the medical technology company’s stock worth $11,463,000 after buying an additional 145,304 shares during the period. Cortina Asset Management LLC boosted its stake in Entellus Medical by 39.2% in the second quarter. Cortina Asset Management LLC now owns 421,897 shares of the medical technology company’s stock valued at $7,708,000 after buying an additional 118,745 shares during the last quarter. Vanguard Group Inc. boosted its stake in Entellus Medical by 5.1% in the second quarter. Vanguard Group Inc. now owns 215,395 shares of the medical technology company’s stock valued at $3,936,000 after buying an additional 10,532 shares during the last quarter. BlackRock Fund Advisors boosted its stake in Entellus Medical by 4.3% in the third quarter. BlackRock Fund Advisors now owns 203,911 shares of the medical technology company’s stock valued at $4,523,000 after buying an additional 8,393 shares during the last quarter. Finally, Wasatch Advisors Inc. boosted its stake in Entellus Medical by 10.0% in the third quarter. Wasatch Advisors Inc. now owns 199,731 shares of the medical technology company’s stock valued at $4,430,000 after buying an additional 18,150 shares during the last quarter. 71.55% of the stock is owned by institutional investors and hedge funds.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.

5 Day Chart for NASDAQ:ENTL

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.